Insiderbarometer: Diese drei Dax-Aktien sind bei ihren Chefs gefragt – und auch für Privatanleger interessant

Bjørn Gulden, Armin Papperger und Michael Sen, all prominent DAX CEOs, have been purchasing shares of their own companies in recent months, according to a September analysis from the Handelsblatt. Adidas, Rheinmetall, and Fresenius saw their CEOs directly invest in their respective stocks during this period. Notably, all three of these stocks have experienced declines over the past year.

Professor Olaf Stotz, an asset management professor at Frankfurt School of Finance & Management, explains that the CEOs' purchases were done contrary to market trends, making these stocks potentially interesting for individual investors. Among the most interesting insider purchases in September is Gulden's acquisition of Adidas shares.

Despite Adidas losing more than 20 percent of its value since the company's Q2 earnings were released in late July, Gulden continued to buy Adidas shares in September, adding nearly half a million euros worth of shares at around 140 euros per share. Stotz considers the Adidas stock to be well-priced, as it trades at about 15 times the analyst average projected net profit for the next twelve months, reflecting analysts' perception that Adidas is undervaluing its "qualities."

Rheinmetall's stock also saw significant insider buying from Papperger, who purchased nearly half a million euros worth of shares at around 950 euros per share. Rheinmetall's stock has dropped more than 50 percent since its record high a year ago but has still gained around 850 percent since the beginning of the Ukraine war in February 2022.

Papperger joined other Rheinmetall executives in buying shares during the past year, but their purchases were the only ones recorded by the Handelsblatt. Fresenius' stock, which has lost only about seven percent over the past year, saw increased buying from Sen in September. Fresenius' stock rallied after the company released strong Q2 results and raised its annual outlook, but it failed to stay sustained.

Sen followed up with additional purchases from Fresenius shares shortly after the announcement, along with Fresenius' new Chief Financial Officer, Sara Hennicken. Although Fresenius' stock has remained relatively low-valued, Stotz still considers it an interesting investment due to its positive outlook in the healthcare sector and relatively low valuation.